Quotient Therapeutics Raises $50M in Initial Funding

Quotient Therapeutics, a Cambridge, MA- and and Cambridge, UK-based company advancing somatic genomics, raised $50M in initial funding.

The round was led by Flagship Pioneering.

The company intends to use the funds to advance development of its platform.

Led by Geoffrey von Maltzahn, Ph.D., and CEO, Quotient Therapeutics is a company working to systematically study the genetic variation and evolution of the trillions of cells inside the human body. Its Somatic Genomics platform reveals links between genes and disease across a broad range of therapeutic areas, enabling the discovery of transformative medicines intended to cure, prevent, or reverse disease.

Created by Flagship scientists in partnership with geneticists at the Wellcome Sanger Institute and the University of Texas Southwestern, this platform is able to study natural selection at the cellular level through four steps: phenotyping of cells from clinical tissue samples, isolation, single cell genotyping, and computation. As a result, naturally selected genes, proteins, and pathways are identified as prospective targets for the development of transformative therapies intended to cure, prevent, or reverse disease. Quotient’s approach will enable the development of first-in-class drugs across a broad range of modalities and therapeutic areas, including immune disease, cardiometabolic disease, infectious disease, oncology, neurodegenerative disease, rare disease, and aging.

Other co-founders include Jacob Rubens, Ph.D., President, and Noubar Afeyan, Strategic Oversight Board Chairman, as well as Professor Sir Mike Stratton, MD, PhD, Inigo Martincorena, PhD, and Peter Campbell, PhD, from the Wellcome Sanger Institute, and Hao Zhu, MD, from University of Texas Southwestern. In addition to von Maltzahn and Rubens, Quotient is led by Scott Hayton, Ph.D., Acting Chief Operating Officer, Caroline Fox, M.D., MPH, Senior Vice President, Head of Genetics and Target Discovery, and Simon Brunner, Ph.D., Co-Founder and Head of Platform. Quotient is co-located in Cambridge, MA  with research facilities in both cities.

Quotient Therapeutics, a Cambridge, MA- and and Cambridge, UK-based company advancing somatic genomics, raised $50M in initial funding. Best wishes to everyone in the group. This will be a huge accomplishment for them in the future.

Shishir Gupta, The Founder & CEO of StartupLanes

About us: StartupLanes is an ecosystem for Startups and Investors. Collaborate or find a co-founder, it’s a platform for Entrepreneurs. We love startups! A place for Angel Investors and Venture Capitalists to find investing opportunities in startups. Validate your idea, Learn & Execute.

Startups looking for funding may apply through StartupLanes Funding Application.

Angel Investors Register Free to explore exciting startup investment opportunities.

Scroll to Top